{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:08:42Z","timestamp":1782421722200,"version":"3.54.5"},"reference-count":84,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"the \u2018Programa XI: Financiaci\u00f3n de Unidades de Excelencia de la Universidad de Salamanca\u2019","award":["It has no number"],"award-info":[{"award-number":["It has no number"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/13543776.2020.1769599","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T23:02:49Z","timestamp":1589410969000},"page":"527-539","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Neurokinin receptor antagonism: a patent review (2014-present)"],"prefix":"10.1080","volume":"30","author":[{"given":"Miguel","family":"Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Research Laboratory on Neuropeptides, Virgen Del Roc\u00edo University Hospital (IBIS), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cove\u00f1as","sequence":"additional","affiliation":[{"name":"Institute of Neurosciences of Castilla Y Le\u00f3n (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, University of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1736-9"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168074"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00031.2013"},{"key":"cit0004","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz M, Cove\u00f1as R, Substance P. In: Substance P. Huhtaniemi I, Martini L, editors. Encyclopedia of endocrine diseases. Second ed. Vol. 1. Oxford: Academic Press; 2019. p. 571\u2013578.","DOI":"10.1016\/B978-0-12-801238-3.95886-0"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-4-3"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-012-0388-3"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2003.09.039"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67199-4_101781"},{"key":"cit0009","first-page":"76","volume":"2","author":"Robinson P","year":"2009","journal-title":"Int J Clin Exp Med"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2015.05.002"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13155"},{"key":"cit0012","first-page":"1","volume-title":"Focus on neuropeptide research","author":"Cove\u00f1as R","year":"2007"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1515\/bmc-2014-0008"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00010-1"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010968"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5383.1640"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-006-9059-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70373-X"},{"key":"cit0019","first-page":"200","volume":"29","author":"Rost K","year":"2006","journal-title":"Med Monatsschr Pharm"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds541"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.804059"},{"key":"cit0022","first-page":"50","volume":"11","author":"Mu\u00f1oz M","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-006-0335-9"},{"key":"cit0024","first-page":"130","volume":"1","author":"Aziz F","year":"2012","journal-title":"Ann Palliat Med"},{"key":"cit0025","unstructured":"Heron Therapeutics Inc. Method of administering emulsion formulations of an NK- 1 receptor antagonist. WO2019152430. 2019."},{"key":"cit0026","unstructured":"Heron Therapeutics Inc. Emulsion formulations of an NK-1 receptor antagonists and uses thereof. US2019000762. 2019."},{"key":"cit0027","unstructured":"Opko Health Inc. Intravenous formulations of neurokinin-1 antagonists. US2016024092. 2016."},{"key":"cit0028","unstructured":"Heron Therapeutics Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester. WO2014093907. 2014."},{"key":"cit0029","unstructured":"Pharmathen SA Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof. US2015165045. 2015."},{"key":"cit0030","unstructured":"Tibet Haisco Pharmaceutical Group Co. Ltd. Medicinal composition for treating emesis. CN103520725. 2014."},{"key":"cit0031","unstructured":"XW Laboratories Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof. WO2020020189. 2020."},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07935.x"},{"key":"cit0033","unstructured":"Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions. WO2018005695. 2018."},{"key":"cit0034","unstructured":"Leo Pharma AS. Novel neurokinin 1 receptor antagonist compounds II. WO2015024203. 2015."},{"key":"cit0035","unstructured":"Leo Pharma AS. Novel neurokinin 1 receptor antagonist compounds. US2015018345. 2015."},{"key":"cit0036","unstructured":"Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat chronic pruritus. WO2020023898. 2020."},{"key":"cit0037","unstructured":"Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat chronic pruritus associated with atopic dermatitis. WO2020023879. 2020."},{"key":"cit0038","unstructured":"Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus. US10617671. 2020."},{"key":"cit0039","unstructured":"Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus. US2020054604. 2020."},{"key":"cit0040","unstructured":"The Regents of the University of California. Itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists. WO2014113564. 2014."},{"key":"cit0041","unstructured":"Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat pruritus. WO2020023873 (2020)."},{"key":"cit0042","unstructured":"Menlo Therapeutics Inc. Use of serlopitant as NK-1 receptor antagonist in pruritus. WO2014209962. 2014."},{"key":"cit0043","first-page":"1789","volume":"60","author":"Arola OJ","year":"2000","journal-title":"Cancer Res"},{"key":"cit0044","first-page":"670","volume":"19","author":"Weiss RB","year":"1992","journal-title":"Semin Oncol"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810615)47:12<2810::AID-CNCR2820471210>3.0.CO;2-4"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1959270"},{"key":"cit0047","unstructured":"Wake Forest University Health Sciences. Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists. WO2015138186. 2015."},{"key":"cit0048","unstructured":"Plus Vitech SL. Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract. WO2016012594. 2016."},{"key":"cit0049","unstructured":"Linnane Pharma AB Novel therapy. WO2018007920. 2018."},{"key":"cit0050","unstructured":"Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives. WO2018136554. 2018."},{"key":"cit0051","unstructured":"Nerre Therapeutics Ltd. Overpitant for the treatment of chronic cough. EP3377064. 2018."},{"key":"cit0052","unstructured":"Amorepacific Corporation. External composition comprising a melanogenesis inhibitor. KR20140107820. 2014."},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790416308"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.697153"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2164"},{"key":"cit0056","unstructured":"Oncoprevent Gmbh. Neurokinin-1 receptor antagonists for use in a method of prevention of cancer. WO2015101596. 2015."},{"key":"cit0057","unstructured":"NK 1 IP Ltd. Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells. US2020054620. 2020."},{"key":"cit0058","unstructured":"Consejo Superior Investigaci\u00f3n. Antagonists of NK1 receptors derived from carbohydrates, production method and medical use. US2019092802. 2019."},{"key":"cit0059","unstructured":"Ospedale San Raffaele Srl. NK-1 antagonists for use in the treatment of ocular pain. WO2019162519. 2019."},{"key":"cit0060","unstructured":"Ferrari Giulio. Novel method. US2014128395. 2014."},{"key":"cit0061","unstructured":"Opko Health Inc. NK-1 antagonists. US2018215729. 2018."},{"key":"cit0062","unstructured":"Vanda Pharmaceuticals Inc. Method of treatment with tradipitant. US2020030307. 2020."},{"key":"cit0063","unstructured":"Univ Henan Normal. Non-peptide tachykinin receptor antagonist preparation method. CN106631972. 2017."},{"key":"cit0064","unstructured":"Ogeda SA NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat. US10624890. 2020."},{"key":"cit0065","unstructured":"Ogeda SA N-acyl-(3-substituted)-(8-substituted)-5, 6-dihydro-[1, 2, 4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders. JP20180062649. 2018."},{"key":"cit0066","unstructured":"F. Hoffmann-La Roche AG. Pyrrolidine derivatives. RU2012127272. 2014."},{"key":"cit0067","unstructured":"Ogeda SA Chiral N-acyl-5,6,7-(8-substituted) tetrahydro [1,2,4] triazolo [4,3- a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof. EA029340. 2018."},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-2114"},{"key":"cit0069","unstructured":"Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antagonists of fish reproduction. US2019169256. 2019."},{"key":"cit0070","unstructured":"Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antagonists of neurokinin B in fish reproduction. WO2016009439. 2016."},{"key":"cit0071","unstructured":"Emory University. Methods of managing conditioned fear with neurokinin receptor Antagonists. US201916369594. 2019."},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-08-0238"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06019gry"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu116"},{"key":"cit0075","unstructured":"California Institute of Technology. Neurokinin antagonists and uses thereof. WO2019090001. 2019."},{"key":"cit0076","unstructured":"The University Court of the University of Edinburgh. Neurokinin B antagonist for use in inhibiting follicle development. WO2016135495. 2016."},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2011.608596"},{"key":"cit0078","unstructured":"IMP Innovations Ltd. Method for treating or preventing hot flushes. WO2015033163. 2015."},{"key":"cit0079","unstructured":"Nerre Therapeutics Limited. Dual NK-1\/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases. WO2016184829. 2016."},{"key":"cit0080","unstructured":"Kandy Therapeutics Ltd. Novel pharmaceutical formulation comprising dual NK- 1\/NK-3 receptor antagonists. WO2019175253. 2019."},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3702"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.07.013"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3148"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2013.07.024"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2020.1769599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T14:59:10Z","timestamp":1620485950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2020.1769599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/13543776.2020.1769599"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2020.1769599","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}